Titre : | Turning down the spice: tackling the problems of synthetic cannabinoids [Editorial] (2023) |
Auteurs : | M. SKUMLIEN ; S. CRAFT ; J. SCOTT ; T. P. FREEMAN |
Type de document : | Article : Périodique |
Dans : | British Medical Journal (Vol.382, n°8398, 16 September 2023) |
Article en page(s) : | art. e076611 |
Langues: | Anglais |
Discipline : | SAN (Santé publique / Public health) |
Mots-clés : |
Thésaurus géographique ROYAUME-UNI ; INTERNATIONALThésaurus mots-clés CANNABINOIDES ; DROGUES DE SYNTHESE ; LEGISLATION ; REDUCTION DES RISQUES ET DES DOMMAGES ; LUTTE ; POLITIQUE |
Résumé : |
National and international policies are key to reducing use and harm
Synthetic cannabinoids, colloquially known as "spice," are a class of structurally diverse novel psychoactive substances that were originally designed to mimic the effects of Delta9-tetrahydrocannabinol, the main psychoactive compound in cannabis. In 2022, the European Monitoring Centre for Drugs and Drug Addiction was monitoring 224 synthetic cannabinoids, with new variations emerging every year. These drugs can produce strong effects at low doses, with potential for serious harms such as addiction and withdrawal, psychosis, seizure, cardiorespiratory problems, and death. Despite this, little is known about how their use can be managed in healthcare settings. [Extract] |
Domaine : | Drogues illicites / Illicit drugs |
Sous-type de document : | Editorial |
Refs biblio. : | 17 |
Affiliation : |
Addiction and Mental Health Group (AIM), Department of Psychology, University of Bath, Bath, UK Bristol Medical School, University of Bristol, Bristol, UK |
Lien : | https://doi.org/10.1136/bmj-2023-076611 |
Accueil